TICKERNERD
Menu
ELVNELVNHealthcare · Biotechnology

ELVN Stock Forecast: Enliven Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 23 Oct 2026
$42
−0.98% on the day

The 14 Wall Street analysts covering Enliven Therapeutics, Inc. hold a median 12-month price target of $74 — +78.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 61 of 100 as at 24 Oct 2026 — in the upper half.

Market cap
$3.0B
Ticker Nerd rank
61/ 100
Median analyst target
$74
Analysts covering
14
Revenue$0.0
Operating income−$37.2M
Net income−$32.5M
Free cash flow−$18.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+11.3%
1M
−9.9%
YTD
+169.6%
1Y
+102.0%
From 52W high
−32.1%
From 52W low
+174.2%
$15
$61
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ELVN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Enliven Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 24 Oct 2026
61/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
91
Value
87
Quality
78
Volatility
76
Accruals
53
Growth
47
Revisions
34
Size
30
Issuance
28

Momentum (91): The shares have been drifting up relative to others.

Issuance (28): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ELVN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ELVN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80Jan 26Apr 26Jul 26Oct 26ELVNHigh $82Median $74Low $69

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
14 Buy0 Hold0 Sell
Low $69Median $74High $82

The green dot is the last close — the median target sits +78.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
19 Oct 2026HC Wainwright & Co.MaintainsBuy$65 → $73
2 Oct 2026Morgan StanleyInitiatesOverweight$70
2 Oct 2026Morgan StanleyInitiatesOverweight—
1 Oct 2026JP MorganInitiatesOverweight$75
1 Oct 2026JP MorganInitiatesOverweight—
18 Aug 2026BarclaysInitiatesOverweight—
18 Aug 2026BarclaysInitiatesOverweight$78
18 Aug 2026MizuhoMaintainsOutperform—
18 Aug 2026MizuhoMaintainsOutperform$62 → $73
18 Aug 2026William BlairInitiatesOutperform—
18 Aug 2026William BlairInitiatesOutperform—
6 Aug 2026Goldman SachsMaintainsBuy—
6 Aug 2026Goldman SachsMaintainsBuy$67 → $80
6 Aug 2026GuggenheimMaintainsBuy$80 → $78
6 Aug 2026GuggenheimMaintainsBuy—
6 Aug 2026StifelMaintainsBuy$80 → $82
6 Aug 2026StifelMaintainsBuy—
21 July 2026Goldman SachsMaintainsBuy$59 → $67
21 July 2026Goldman SachsMaintainsBuy—
9 July 2026HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ELVN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

Performance

ELVN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 23 Oct 2026, Enliven Therapeutics, Inc. returned +102.0% against +14.3% for the S&P 500, dividends included.

ELVN vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Jan 26Apr 26Jul 26Oct 26ELVNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ELVN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

Enliven Therapeutics, Inc. (ELVN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−22.7×

Cheaper than 97% of US stocks

Price / sales
—
Price / book
3.4×

Cheaper than 27% of US stocks

EV / EBITDA
−17.3×

Cheaper than 89% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−15.3%

Higher than 33% of US stocks

Return on assets
−11.0%

Higher than 26% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Enliven Therapeutics, Inc. (ELVN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Enliven Therapeutics, Inc. has a market value of $3.0B and an enterprise value of $2.1B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$105.9M.

  • Diluted earnings per share, trailing twelve months: $−1.67.

  • Free cash flow in the twelve months to 30 June 2026: −$67.0M.

  • Shares outstanding: 73.3M.

  • Trailing P/E: −22.7×; forward P/E: −17.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Enliven Therapeutics, Inc. employs 67 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 24 Oct 2026

Data provided by Twelve Data

Peers

ELVN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ELVNEnliven Therapeutics, Inc.$3.0B61
PBLSParabilis Medicines, Inc.$2.9B0
DNLIDenali Therapeutics, Inc.$2.9B60
DYNDyne Therapeutics, Inc.$2.9B23
VKTXViking Therapeutics, Inc.$3.1B35
IRONDisc Medicine, Inc.$2.9B38
NRIXNurix Therapeutics, Inc.$2.8B94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Enliven Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ELVN news & analysis

Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year

PRNewsWire · 14 Oct 2026positive

Enliven Therapeutics appointed Kristine Ball to its Board of Directors, effective immediately. The company said it is preparing for late-stage development and commercialization and plans to initiate relcobatinib’s pivotal Phase 3 trial before year-end.

Why it matters — The appointment comes as Enliven prepares for a planned pivotal trial and advances its late-stage development and commercialization efforts.

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter

CNBC Television · 6 Oct 2026neutral

Goldman Sachs lead U.S. biotech analyst Salveen Richter discussed biotech innovations in China on CNBC’s “Closing Bell Overtime.” The headline says large biopharma companies are looking at China assets.

Why it matters — The discussion concerns biotech industry activity in China, but the provided text does not identify a direct connection to Enliven Therapeutics.

Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia

PRNewsWire · 6 Oct 2026positive

Enliven Therapeutics said it reached alignment with the FDA on the final design of the ENABLE-2 Phase 3 pivotal trial of relcobatinib (ELVN-001) in previously treated chronic myeloid leukemia. The company remains on track to initiate the trial before year-end 2026.

Why it matters — FDA alignment on trial design is a development milestone for ELVN’s relcobatinib program, and the planned initiation timeframe provides an update on the trial’s progress.

This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Benzinga · 2 Oct 2026positive

A Wall Street analyst initiated coverage on Enliven Therapeutics with a bullish stance, according to Benzinga's roundup of top analyst initiations for Friday. The item lists Enliven Therapeutics among several companies receiving new coverage from analysts.

Why it matters — An analyst beginning coverage of Enliven Therapeutics on a bullish note could draw fresh attention from investors tracking the stock.

Enliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 16 Sept 2026neutral

Enliven Therapeutics presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published on Seeking Alpha. The item provides a record of the company's remarks at the investor conference.

Why it matters — For Enliven Therapeutics watchers, this transcript offers insight into management's public commentary at a major financial healthcare conference.

FAQ

Frequently asked questions about ELVN stock

What is the ELVN stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Enliven Therapeutics, Inc. have a median 12-month price target of $74, with estimates ranging from $69 to $82. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ELVN stock a buy right now?

Of the 14 analysts covering Enliven Therapeutics, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Enliven Therapeutics, Inc. 61 out of 100 across roughly 4,600 US stocks as at 24 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ELVN?

As at 24 Oct 2026, Enliven Therapeutics, Inc. ranks 61 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (91 of 100).

Will ELVN stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +78.2% from the last close, and Ticker Nerd's factor model ranks Enliven Therapeutics, Inc. 61 out of 100 as at 24 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ELVN stock forecast for 2030?

No analyst covering Enliven Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $69 to $82 over the next 12 months.

How has ELVN stock performed over the past year?

Enliven Therapeutics, Inc. returned +102.0% over the 12 months to 23 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Enliven Therapeutics, Inc. do?

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for cancer.

What is the latest news on ELVN?

The most recent item we track (PRNewsWire, 14 Oct 2026): "Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year". Enliven Therapeutics appointed Kristine Ball to its Board of Directors, effective immediately. The company said it is preparing for late-stage development and commercialization and plans to initiate relcobatinib’s pivotal Phase 3 trial before year-end.

Company

About Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for cancer. The company’s current pipeline centers on precision oncology programs designed to target clinically validated pathways with greater selectivity and improved tolerability. Its lead candidates include ELVN-001, a kinase inhibitor being evaluated for chronic myeloid leukemia, and ELVN-002, a CNS-penetrant HER2 inhibitor being studied in HER2-altered solid tumors such as non-small cell lung cancer. Enliven Therapeutics, Inc. operates in the oncology drug development market, where small molecule inhibitors play an important role in addressing unmet needs across liquid and solid tumors. The company is headquartered in Boulder, Colorado, and is organized around research and early-stage clinical development of targeted cancer therapies.

CEO Mr. Richard A. Fair M.B.A. · 67 employees · United States · https://www.enliventherapeutics.com